Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IFRX
stocks logo

IFRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
29.50K
-76.18%
-0.138
+71.88%
26.17K
-6330.95%
-0.123
-5.13%
--
--
-0.127
-39.68%
Estimates Revision
The market is revising Downward the revenue expectations for InflaRx N.V. (IFRX) for FY2025, with the revenue forecasts being adjusted by -31.83% over the past three months. During the same period, the stock price has changed by -33.33%.
Revenue Estimates for FY2025
Revise Downward
down Image
-31.83%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+11.62%
In Past 3 Month
Stock Price
Go Down
down Image
-33.33%
In Past 3 Month
Wall Street analysts forecast IFRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IFRX is 11.14 USD with a low forecast of 2.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast IFRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IFRX is 11.14 USD with a low forecast of 2.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.100
sliders
Low
2.00
Averages
11.14
High
24.00
Current: 1.100
sliders
Low
2.00
Averages
11.14
High
24.00
Leerink
Outperform -> Market Perform
downgrade
$2
2025-12-03
New
Reason
Leerink
Price Target
$2
2025-12-03
New
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded InflaRx to Market Perform from Outperform with a $2 price target.
Leerink
Joseph Schwartz
Outperform -> Market Perform
downgrade
$5 -> $2
2025-12-03
New
Reason
Leerink
Joseph Schwartz
Price Target
$5 -> $2
2025-12-03
New
downgrade
Outperform -> Market Perform
Reason
Leerink analyst Joseph Schwartz downgraded InflaRx to Market Perform from Outperform with a price target of $2, down from $5. InflaRx delivered unexpectedly positive Phase 2a data for INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria, with the HS results looking compelling enough to justify a Phase 2b trial, the analyst tells investors in a research note. Despite management's view that its EUR 44.4M cash balance can fund operations into 2027, further financing appears likely and could be notably dilutive at the current valuation.
Raymond James
Ryan Deschner
Outperform
maintain
$2 -> $9
2025-11-11
Reason
Raymond James
Ryan Deschner
Price Target
$2 -> $9
2025-11-11
maintain
Outperform
Reason
Raymond James analyst Ryan Deschner raised the firm's price target on InflaRx to $9 from $2 and keeps an Outperform rating on the shares. Inflarx reported "strong" early efficacy and safety data from their oral C5aR inhibitor INF904 in Hidradenitis Suppurative patients in a Phase 2a autoimmune disease basket study, the analyst tells investors in a research note. The response of HS patients at 4 weeks is very positive, given competitive levels of HiSCR response were seen at 4 weeks, further increasing for at least four more weeks post-treatment, and Raymond James believes there is ample room for an oral drug with a novel mechanism in the HS market.
Oppenheimer
Andreas Argyrides
Outperform
maintain
$3 -> $7
2025-11-11
Reason
Oppenheimer
Andreas Argyrides
Price Target
$3 -> $7
2025-11-11
maintain
Outperform
Reason
Oppenheimer analyst Andreas Argyrides raised the firm's price target on InflaRx to $7 from $3 and keeps an Outperform rating on the shares following positive results from the Phase 2a basket study of INF904 in hidradenitis suppurative and chronic spontaneous urticaria. The firm sees INF904 emerging as a best-in-class oral therapy with favorable safety and a superior PK/PD profile vs. avacopan. The robust results derisk INF904's profile, warranting further development in both indications, Oppenheimer adds.
Cantor Fitzgerald
NULL -> Overweight
maintain
$3 -> $8
2025-11-11
Reason
Cantor Fitzgerald
Price Target
$3 -> $8
2025-11-11
maintain
NULL -> Overweight
Reason
Cantor Fitzgerald raised the firm's price target on InflaRx to $8 from $3 and keeps an Overweight rating on the shares. InflaRx's C5aR inhibitor is looking good, and the company should pursue the efficacy signal in a larger, longer Phase 2B hidradenitis suppurative study, the analyst tells investors in a research note.
Guggenheim
Buy
upgrade
$10 -> $22
2025-11-10
Reason
Guggenheim
Price Target
$10 -> $22
2025-11-10
upgrade
Buy
Reason
Guggenheim raised the firm's price target on InflaRx to $22 from $10 and keeps a Buy rating on the shares after the company announced topline data from a Phase 2a basket study exploring INF904 in hidradenitis suppurativa and chronic spontaneous urticaria. The firm raised its view of the odds of success in HS to 65% from 30% following the data and models peak HS sales of about $1.5B.
See All Ratings

Valuation Metrics

The current forward P/E ratio for InflaRx NV (IFRX.O) is -1.83, compared to its 5-year average forward P/E of -2.43. For a more detailed relative valuation and DCF analysis to assess InflaRx NV 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.43
Current PE
-1.83
Overvalued PE
-1.36
Undervalued PE
-3.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.13
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.97
Undervalued EV/EBITDA
-4.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1899.94
Current PS
0.00
Overvalued PS
9033.75
Undervalued PS
-5233.86
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 425.33% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

IFRX News & Events

Events Timeline

(ET)
2025-12-01
08:50:00
HighPeak Energy Borrow Rate Soars to 58.46%
select
2025-11-14 (ET)
2025-11-14
08:45:01
Significant Borrowing Rate Hikes Among Liquid Assets
select
2025-11-10 (ET)
2025-11-10
08:00:07
InflaRx announces Phase 2a results for INF904 in HS and CSU.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
11-10NASDAQ.COM
Most Active Stocks in Pre-Market Trading on November 10, 2025: IFRX, GREE, IPHA, TSLL, SQQQ, NVDA, PFE, BBAI, OSCR, IONQ, HLN, THS

  • NASDAQ 100 Pre-Market Performance: The NASDAQ 100 Pre-Market Indicator is up 380.3 points to 25,440.11, with a total pre-market volume of 219,886,694 shares traded.

  • Active Stocks Overview: InflaRx N.V. (IFRX) and Greenidge Generation Holdings Inc. (GREE) are among the most active stocks, with IFRX trading at $2.01 and GREE at $2.02, both showing positive movements.

  • Earnings Reports and Forecasts: IFRX and Innate Pharma S.A. (IPHA) are scheduled to release earnings reports soon, with IPHA showing a significant forecasted increase in earnings per share compared to last year.

  • Stock Recommendations: Several stocks, including NVIDIA Corporation (NVDA) and IonQ, Inc. (IONQ), are currently in the "buy range" according to Zacks, indicating positive market sentiment.

[object Object]
Preview
2.0
11-10Benzinga
Viasat Shares Rise Approximately 13%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Viasat's Financial Performance: Viasat Inc. reported adjusted earnings of 9 cents per share, significantly beating market expectations of a loss, leading to a 13.2% increase in its share price during pre-market trading.

  • Notable Gainers in Pre-Market Trading: Several stocks saw significant gains, including Masonglory Ltd (up 113.5%), Integrated Media Technology Ltd (up 117.1%), and Greenidge Generation Holdings Inc (up 57.6%) following positive developments.

  • Major Losers in Pre-Market Trading: Lazydays Holdings Inc experienced a sharp decline of 38.6% after announcing plans to delist, while CleanCore Solutions Inc fell 30.8% due to a withdrawal of its registration statement.

  • Market Activity Overview: The article highlights various stocks' movements in pre-market trading, showcasing both significant gains and losses, reflecting a volatile market environment.

[object Object]
Preview
9.5
11-10NASDAQ.COM
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours

  • InflaRx N.V. Surge: InflaRx N.V. saw a significant after-hours increase of 63.41% to $2.01, driven by the anticipation of topline data from its Phase 2a trial and third-quarter financial results expected on Monday.

  • Rallybio Corp. Performance: Rallybio Corp. rose 12.84% to $0.71 after reporting a third-quarter net income of $16.0 million, reversing a loss from the previous year, although revenue slightly declined.

  • FibroBiologics Inc. Growth: FibroBiologics Inc. climbed 13.51% to $0.40 after hours, following a previous corporate update and third-quarter financial results released on October 31.

  • Cellectis S.A. Recovery: Cellectis S.A. increased by 6.58% to $3.40 after reporting a third-quarter net income of $589 thousand, a significant improvement from a loss in the prior year, with revenues more than doubling.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is InflaRx NV (IFRX) stock price today?

The current price of IFRX is 1.1 USD — it has increased 7.84 % in the last trading day.

arrow icon

What is InflaRx NV (IFRX)'s business?

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

arrow icon

What is the price predicton of IFRX Stock?

Wall Street analysts forecast IFRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IFRX is 11.14 USD with a low forecast of 2.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is InflaRx NV (IFRX)'s revenue for the last quarter?

InflaRx NV revenue for the last quarter amounts to 23.83K USD, decreased -80.75 % YoY.

arrow icon

What is InflaRx NV (IFRX)'s earnings per share (EPS) for the last quarter?

InflaRx NV. EPS for the last quarter amounts to -0.18 USD, decreased -40.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for InflaRx NV (IFRX)'s fundamentals?

The market is revising Downward the revenue expectations for InflaRx N.V. (IFRX) for FY2025, with the revenue forecasts being adjusted by -31.83% over the past three months. During the same period, the stock price has changed by -33.33%.
arrow icon

How many employees does InflaRx NV (IFRX). have?

InflaRx NV (IFRX) has 74 emplpoyees as of December 05 2025.

arrow icon

What is InflaRx NV (IFRX) market cap?

Today IFRX has the market capitalization of 74.52M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free